pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
pharmadog news

Browse

1,088 stories matching this filter · ← front page

★ save view↓export CSV
rangeto
sort
recentoldestsourcealpha
source
STAT811Endpoints611BioPharma Dive235onclive165Fierce Biotech80BioSpace78raps32globenewswire health26fda press
therapy area
allOncology81Cardiology27Psychiatry & CNS21Vaccines17Immunology17Rare Disease12Hepatology6
  • STAT+: Even at a meeting in Rome, FDA shifts are top of mind for gene therapy field
    Cell and gene therapy makers met in Rome to discuss the field's outlook in Europe. One main topic of conversation: the FDA.
    STAT · 2mo ago↗ source
  • STAT+: OpenAI wants to ‘have their cake and eat it too’ with health AI policy recommendations
    Policy recommendations in OpenAI's blueprint for unlocking AI’s potential to change health care are reasonable, but also self-serving, experts say.
    STAT · 2mo ago↗ source
  • Opinion: Trump’s executive order on psychedelics is the right move. But is my field ready for it?
    The psychedelics field is getting what it has long wanted. Now it has to step up.
    STAT · 2mo ago↗ source
← prev
page 39 of 44
next →
21
fda recalls20
fda medwatch16
Hematology6
Pulmonology5
Infectious Disease4
Ophthalmology3
Dermatology2
  • Simlukafusp Alfa Regimens Show Manageable Safety and Activity But Do Not Outperform SOC in Metastatic RCC
    Simlukafusp alfa plus atezolizumab with/without bevacizumab was safe and active but did not improve upon responses with SOC treatments in metastatic RCC.
    onclive · 2mo ago↗ source
  • Dr Cohen on Frontline Chemotherapy Selection in Metastatic Pancreatic Cancer
    Deirdre J. Cohen, MD, MS, discusses clinical decision-making and the comparative efficacy of FOLFIRINOX and NALIRIFOX in metastatic pancreatic cancer.
    onclive · 2mo ago↗ source
  • STAT+: Did AI really beat doctors at diagnosis?
    In this edition of STAT Health Tech: A high-profile study on AI's diagnostic capabilities, role of telehealth in abortion access, and an Epic lawsuit.
    STAT · 2mo ago↗ source
  • Dr Pant on Managing Toxicities With Daraxonrasib in PDAC
    Shubham Pant, MD, MBBS, discusses the management of dermatologic and GI toxicities associated with the RAS(ON) inhibitor daraxonrasib.
    onclive · 2mo ago↗ source
  • HS-10504 Shows Promising Activity in EGFR C797S–Mutant NSCLC After TKI Resistance
    Phase 1 data show HS-10504 yields encouraging responses and manageable safety in EGFR C797S–mutant NSCLC post TKI therapy.
    onclive · 2mo ago↗ source
  • STAT+: Pharma’s reputation among patient groups rose last year, but concerns remain over access and pricing
    The pharma industry saw its reputation among patient groups inch up last year, a new survey finds, but concerns remain over access and pricing.
    STAT · 2mo ago↗ source
  • STAT+: A new attack on AMA’s billing codes
    A key GOP lawmaker is broadening the party's efforts to combat health care fraud.
    STAT · 2mo ago↗ source
  • Breast Cancer Experts Preview Abstracts to Watch at the 2026 ESMO Breast Cancer Congress
    Experts in a range of breast cancer subtypes highlight research data being presented at the 2026 ESMO Breast Cancer Congress.
    onclive · 2mo ago↗ source
  • The Type of Fat—Not the Amount—Fuels Pancreatic Cancer
    Research from Yale Cancer Center showed that the type of fat consumed may matter more than amount in pancreatic cancer.
    onclive · 2mo ago↗ source
  • STAT+: Are analysts too quick to gloss over Lilly’s liver case?
    Cytokinetics' Myqorzo's trial results, Johnson & Johnson's IBD therapy, and more biotech news from The Readout
    STAT · 2mo ago↗ source
  • Iopofosine I 131 Follow-Up Data Show Strong Efficacy in Waldenström Macroglobulinemia
    Iopofosine I 131 produced strong responses in Waldenström macroglobulinemia, according to 12-month folllow-up data from CLOVER WaM requested by the FDA.
    onclive · 2mo ago↗ source
  • Dr McGregor on Key End Points of the STRIKE Trial of Tivozanib Plus Pembrolizumab in RCC
    Bradley McGregor, MD, discusses the end points that will be evaluated in the phase 3 STRIKE trial of adjuvant tivozanib plus pembrolizumab in high-risk RCC.
    onclive · 2mo ago↗ source
  • STAT+: Pharmalittle: We’re reading about RFK Jr. targeting antidepressants, J&J pushing an IBD drug, and more
    HHS Secretary Robert F. Kennedy Jr. announced initiatives to rein in prescribing of SSRIs, the most widely used antidepressants
    STAT · 2mo ago↗ source
  • Dr Kuykendall on the Evolving JAK Inhibitor and Transplant Considerations in Myelofibrosis
    Andrew Kuykendall, MD, explains considerations for JAK inhibitor sequencing and the use of transplant in myelofibrosis.
    onclive · 2mo ago↗ source
  • New Endometrial Targets Beyond HER2
    Interest in endometrial cancer extends well beyond HER2, and the faculty review a growing pipeline of antibody drug conjugates directed at additional targets. Discussion includes why TROPE2 and oth…
    onclive · 2mo ago↗ source
  • Coordinating Care in Multiple Myeloma Across Practice Settings
    onclive · 2mo ago↗ source
  • EGFR-Mutated NSCLC: Molecular Reassessment at Disease Progression
    In this case-based segment, Dr. Sands presents a patient with EGFR-mutated metastatic non-small cell lung cancer who has progressed after first-line combination therapy with an EGFR tyrosine kinase…
    onclive · 2mo ago↗ source
  • New Understandings of Treatments, End Points, and Disease Biology Expand MCL Horizons
    Lore Gruenbaum, PhD, discusses the direction mantle cell lymphoma is headed in addition to other critical areas of unmet needs.
    onclive · 2mo ago↗ source
  • What you need to know about hantavirus (don’t panic)
    The latest on the abortion pill, paternal deaths, and more health news from Morning Rounds
    STAT · 2mo ago↗ source
  • STAT+: Cytokinetics drug Myqorzo meets twin efficacy goals in study of genetic heart disease
    A Cytokinetics heart disease drug — already approved in one indication — succeeded in another Phase 3 trial, a potential boost for sales.
    STAT · 2mo ago↗ source
  • Opinion: The ‘brain drain’ narrative about health professionals misses half of the story
    52 health professionals returned home to 43 countries. Here are the unexpected challenges and opportunities they faced.
    STAT · 2mo ago↗ source
  • Opinion: The cruise ship hantavirus outbreak is a warning sign to the U.S.
    Leaving the WHO means the U.S. lacks access to necessary information about infectious disease.
    STAT · 2mo ago↗ source